glp-1 coverage medicaid of GLP-1s for obesity may be restricted | KFF posted on the topic McKee's proposed FY2027 budget drops

Chang J, Wu T, Greenfield JR, Samocha-Bonet D, Horowitz M, Rayner CK

Tirzepatide did not increase risks of adverse renal events, urinary tract infections, nephrolithiasis (kidney stones), acute kidney injury, or renal cancer compared to placebo, insulin, or other GLP-1 receptor agonists

Notably, that protective effect held even among patients who were not obese suggesting the medication itself may be doing more than simply reducing weight

Katrine Strandberg-Larsen, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

It can signal healing, but it can also be present and harmful in the context of chronic disease

The proliferation of virtual pharmacies that exist largely to prescribe GLP-1s, with no other long-term patient-doctor relationship, adds to the risk that people go on these drugs without appropriate supervision and support